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ABSTRACT
Targeted photodynamic therapy (PDT) in head/neck cancer
patients with a conjugate of the anti-epidermal growth factor
receptor (EGFR) antibody, Cetuximab and a phthalocyanine
photosensitizer IR700DX is under way, but the exact mecha-
nisms of action are still not fully understood. In this study,
the EGFR-overexpressing human head/neck OSC-19-luc2-
cGFP tumor with transfected GFP gene was used in a skin-
fold window chamber model in BALB/c nude mice. The
uptake and localization of the conjugate in the tumor and its
surrounding normal tissues were studied by an intravital
confocal laser scanning microscopy with image analyses. The
tumor was also irradiated with 690 nm laser light 24 h after
conjugate administration. The vascular and tumor responses
were examined by morphological evaluation and immunohis-
tochemistry (IHC). The amount of conjugate in the tumor
peaked at 24–48 h after injection. Image analyses of colocal-
ization correlation parameters demonstrated a high fraction
of the conjugate IR700DX colocalized in the GFP-expressing
tumor cells. PDT-treated tumors showed extensive necrotic/
apoptotic destruction with little vascular damage, while IHC
showed no HIF-1a expression and decreased EGFR and Ki67
expression with activated caspase-3 overexpression, indicating
a direct killing of tumor cells through both necrotic and
apoptotic cell death.
INTRODUCTION
The worldwide incidence of head and neck cancers is estimated
to be more than 550 000 each year with the mortality rate of
about 300 000 (1,2). The tumors mainly arise from the squa-
mous cell linings with more than 90% squamous cell carcinoma
(3). Because of the complexity of the head and neck region
with its critical structures, the treatment options do not only
depend on the type and stage, but also the anatomic location of
the tumor. The conventional treatment includes surgery or
radiotherapy for early-stage I/II cancer (4–6), while combina-
tions of surgery, radiotherapy and chemotherapy for advanced
stage III/IV cancer (7–9). However, both surgery and radiother-
apy often cause severe damage to surrounding normal tissues
with a loss of their functions (10,11). Such morbidities have
encouraged the field to search for new treatment alternatives for
this disease.
The concept of photodynamic therapy (PDT) is attractive for
cancer treatment (12–14) because the combination of a tumor-
localizing photosensitizer with selective light delivery has the
potential to provide a selective treatment for cancer with low mor-
bidity (15). Effective PDT with the first generation photosensitizer
such as hematoporphyrin derivative or porfimer sodium was shown
in 1990s in the treatment of head and neck cancers (16), but pro-
longed skin photosensitivity with limited treatment depth of tumor
(17,18) led investigators to look for second-generation photosensi-
tizers with favorable properties of photochemistry, photophysics
and photobiology (19,20). The European Medicines Agency
(EMA)-approved PDT for palliative treatment of head and neck
cancer with meta-tetra(hydroxyphenyl)chlorin (mTHPC, temo-
porfin) as a photosensitizer has shown to obtain complete response
rates comparable to surgical treatment as well as to maintain good
functional and cosmetic outcome in the treatment of squamous cell
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carcinoma of the lip, oral cavity and pharynx (19,21,22). For larger
lesions, surgery is more effective, but with the potential side effects
of severe morbidities. Interstitial irradiation of temoporfin with its
strong absorption of far-red wavelengths can enhance treatment
depth, so that it may make it possible to treat larger tumors (23–
25). However, the collateral phototoxicity of normal tissues to
mTHPC-based PDT requires strict light protection protocols to
prevent unwanted PDT effects. This has led to a search for alterna-
tive approaches that spare normal tissues.
Targeted PDT based on a photosensitizer linked to a targeting
moiety with an affinity for tumor cells can improve the selective
tumor distribution of the photosensitizer. Such targeting moieties
include monoclonal antibodies, peptides, carbohydrates, folic
acid and others (26). Epidermal growth factor (EGF), a protein
produced in the body, attaches to its receptor (EGFR) of cells to
trigger cellular proliferation. EGFR has been found to be over-
expressed on the cell surface of several types of tumors includ-
ing head and neck squamous cell carcinoma. Cetuximab, a
chimeric (mouse/human) monoclonal antibody, is able to block
the effect of EGF by binding EGFR, and was approved by
EMA in 2004 and FDA in 2006 as a therapy for the treatment
of patients with locally advanced squamous cell carcinoma of
the head and neck in combination with radiation therapy (27).
Phthalocyanines, a family of potent photosensitizers with their
favorable properties of chemical stability, high fluorescence
quantum yield and redshifted light absorption for optimal tissue
penetration, have already been used for PDT of cancer patients
in Russia (28). In general, hydrophilic phthalocyanines, such as
IRDye700DX (IR700DX), have little photodynamic efficacy due
to poor localization and are therefore commonly used to form a
conjugate with a targeting moiety (29–31). IR700DX conjugated
with an EGFR antibody has been shown to serve as both a diag-
nostic and a PDT-therapeutic agent (30,31). Based on a number
of preclinical studies with promising results (31,32), a clinical
trial with cetuximab and IR700DX was recently initiated by
Rakuten Aspyrian, Inc. (https://clinicaltrials.gov/ct2/show/
NCT02422979) (33) in patients with recurrent head and neck
cancer. Although a rapid direct necrotic killing effect on tumor
cells in vitro was noticed after the targeted PDT with IR700DX
(31,32), the mode of cell death using this modality (including
apoptosis) is still not fully understood. Further, the biological
system of tumor cells cultured in vitro is significantly different
from that of tumor tissue in vivo. Any antibody–dye conjugates
including cetuximab/IR700DX go through the vascular system
(including endothelium and tissues beneath its basal layer) and
interstitial tissue space before reaching tumor cells in tumor tis-
sue after systemic administration. Tumor destruction by a tar-
geted PDT may thus involve direct and indirect (via initial
vascular damage) killing effects on tumor cells that depend on
the intratumoral localization of the conjugate. To better under-
stand the correlation of kinetic uptake and localization patterns
of such a conjugate in tumor with vascular and tumor responses
after PDT, we have utilized intravital microscopy with window
chamber technologies, such as the dorsal skin-fold, to image
real-time dynamic processes in vivo (34–36). With this approach
and using a mouse window chamber human head and neck
OSC-19-luc2-cGFP tumor model in vivo with EGFR expression
and transfected GFP genes, the aims of this study were to inves-
tigate (1) the kinetic patterns of the uptake and localization of
the conjugate, cetuximab–IR700DX, in the tumor, (2) the vascu-
lar and tumor responses after the targeted PDT and (3) the
mechanisms of action of the targeted PDT on tumors with
histopathology and immunohistochemistry.
MATERIALS AND METHODS
Human OSC-19-luc2-cGFP head and neck tumor cell line. The OSC-19-
Luc2-cGFP (OSC-19) cell line was originally established in Japan from a
patient with a well-differentiated squamous cell carcinoma of the tongue
(37) and the OSC-19 cell line with transfected genes of luciferase 2
(luc2), and green fluorescent protein (GFP) was described previously (38).
The cells were cultured in DMEM (Invitrogen, Carlsbad, CA) containing
4.5 g D-glucose L1, 110 mg L1 sodium pyruvate L1, 580 mg L-
glutamine L1 supplemented with 10% FCS (Lonza, Basel, Switzerland),
100 IU mL1 penicillin, 100 mg mL1 streptomycin (Invitrogen), 19
minimal essential medium (MEM) nonessential amino acids solution and
19 MEM vitamin solution at 37°C in a humidified 5% CO2 atmosphere.
The passages of 10–40 of the cell line were used in this study.
Animals and skin-fold window chamber tumor model. An approval for
the protocol of this study was obtained from the Erasmus University
Medical Center and The Netherlands National Committee for the
protection of animals used for scientific purposes. All experiments were
conducted according to The National and European Ethical Committees’
Guidelines on Animal Welfare. The skin-fold window chamber tumor
model was made according to previously described procedures (36,39).
Briefly, female BALB/c athymic nude mice from Janvier Labs (Saint-
Berthevin Cedex, France) were 12 weeks old, weighed between 17 and
25 g, fed with chlorophyll-free complete food for 2 weeks prior to
experiments and kept under specific pathogen-free conditions. After
being anesthetized with inhalation of isoflurane/O2, a dorsal skin flap of
a mouse was made by dissecting the dorsal skin under aseptic conditions
and a window chamber was then implanted on the dorsal skin flap. The
OSC-19 cells had subcutaneously been inoculated into the dorsal skin
flap (5 9 104 cells suspended in 10 µL serum-free medium) before a
cover glass was placed to close the chamber. The window chamber was
made of a synthetic material, polyether ether ketone (PEEK) that is inert
and does not provoke immune reactions. The animals with the chamber
were individually kept in a cage in a climate-controlled room with 32°C
and 50%–60% humidity. The individual housing of mice prevents
potential damage to the window chamber by other mice, while the high
temperature and humidity avoid the cooling down and dehydration of the
skin flap. Mice fitted with this chamber showed normal behaviors with
Figure 1. Microscopic green fluorescent protein (GFP)-expressing human
head and neck OSC19 squamous cell carcinoma in a mouse skin-fold win-
dow chamber model. The image was made with the intravital LSM (bar:
500 µm). For the details, see the Section of Materials and Methods.
Photochemistry and Photobiology, 2020, 96 709
full capacity of motion and climbing. The general conditions of the
window chamber together with tumor growth and its blood circulation
were regularly checked by a confocal microscope at a low magnification
to determine a best time to start the experiment with an average of
7 days after implantation of tumor cells (Fig. 1).
Intravital imaging. Experiments were started when the tumor showed
microvascularization and growth (area: 0.5–2.5 mm2). The animals
(n = 8) were sedated with the inhalation of isoflurane/O2 and placed on a
37°C temperature-controlled stage of a confocal microscope. The
fluorescent tumor GFP (Ex/Em: 488/BP505–530 nm) and conjugate
IR700DX (Ex/Em: 633/LP650 nm) in tumor and its surrounding normal
tissues were optically sectioned to a 9 µm thickness and imaged by the
Zeiss laser scanning microscope (LSM) 510–Axiovert 200M (Carl Zeiss,
Thornwood, NY) with a 109 objective at 0, 4, 24 and 48 h after i.v.
administration of the conjugate cetuximab–IR700DX (100 µL of
1 mg mL1 from Rakuten Aspyrian Inc. San Diego, USA) via the tail
vein. A mode of the system was set to enable the PC to control the
microscope, xy-table, z-positioning and image capture with three
detection channels of transmission, GFP and IR700DX. During the study
period of 48 h, the animals were kept under reduced light conditions to
avoid possible phototoxic effects of the conjugate, after which all
animals were sacrificed by cervical dislocation.
Since one image made by the LSM system with a 109 objective can-
not cover the field of a whole tumor and its surrounding normal tissues,
nine images were acquired in each of the three channels to visualize an
area large enough to include a tumor and its surrounding normal tissues.
Based on the transmission and tumor GFP images, the areas of tumor,
vessels and connective tissue were identified. At least three regions of
interest were randomly chosen in the areas of each type of tissues for
image analyses with ImageJ to study the kinetic uptake of the conjugate
by tumor and its surrounding normal tissues.
For the colocalization study, a total of eight live mice with 1–3 tumors
per mouse were used. Eight optically sectioned serial confocal fluorescent
images (9 µm thickness) of conjugate IR700DX and eight corresponding
tumor GFP images were acquired using the Zeiss LSM 510 with a 209
objective in each tumor at 0 and 4, 24 and 48 h after i.v. administration of
conjugate via the tail vein. One of the eight conjugate IR700DX images,
randomly chosen with its respective tumor GFP image, was used to carry
out the colocalization image analyses with the Fiji software (http://fiji.sc)
of the image processing program ImageJ. The background (including
dark current of the microscopy) of the images of the tissue samples taken
from the animals prior to the conjugate injection was subtracted. The
coloc2 plugin in the Fiji version was used to calculate pixel-intensity cor-
relation-based colocalization parameters of Pearson’s R value (a measure
of the strength of the linear relationship between two different types of
fluorescent signal images) and Mander’s tM1 parameter (a measure of
the colocalization coefficient between two images).
Targeted PDT in four tumor-bearing animals was performed on the
tumors under 690 nm laser irradiation (ML7700, Modulight, Inc., Fin-
land) through a frontal light distributor (Medlight SA, Ecublens, Switzer-
land) to a dose of 100 J cm2 (at 50 mW cm2) 24 h after conjugate
administration. Normal and tumor vascular responses prior to and 5-min,
2, 24 and 48 h after light exposure were determined by transmission
microscopy with a 109 objective (Leica SP5 AOBS Multiphoton lasers,
Wetzlar, Germany). In addition, the fluorescent rhodamine dextran
2 MDa was immediately (<10 min) imaged after its i.v. administration
(100 µL of 1 mg mL1) with the same microscopic system (Ex/Em: 555/
580 nm) to study vascular leakage in the tumor and surrounding normal
tissues at 2 h after targeted PDT.
Histopathology and immunohistochemistry (IHC). The destructive
effects of the targeted PDT on two of the four tumors were examined by
histopathological evaluation and IHC. The other two tumors were too
small to be used for such study. Three untreated tumors were also
included as controls. Normal and tumor tissues of the skin-fold window
chamber were harvested at 48 h after the targeted PDT, immediately
frozen in liquid nitrogen and stored in 80°C before use. The tissues
were fixed in a 10% buffered formalin solution and paraffin-embedded.
Three lm tissue sections were then made and stained with hematoxylin
and eosin (H&E). In addition, the sections were immunostained using the
Dako EnVision + system (K8012, Dako Cooperation, CA, USA) and
Dako Autostainer. Deparaffinization, rehydration and target retrieval were
performed in a Dako proteinase K (for EGFR) or a Dako PT-link (for
hypoxia-inducible factor 1-alpha (HIF-1a), Ki67, cleaved caspase-3 and
LC3) and EnVision Flex target retrieval solution. Endogenous peroxidase
was blocked using a Dako blocking reagent for 5 min followed by
incubation at 4°C over night with primary antibody against EGFR (mouse
monoclonal antibody, Clone H11, 1:200 dilution, Dako Corporation, CA,
USA) and at room temperature for 30 min with primary antibodies
against HIF-1a (rabbit polyclonal antibody, 1:300 dilution, Novus Europe,
UK), Ki67 (mouse monoclonal antibody, Clone MIB-1, 1:150 dilution,
DakoCytomation, Denmark A/S), cleaved caspase-3 (rabbit polyclonal
antibody, 1:100 dilution, Novus Europe, UK) and LC3 (#2775, 1:1000
dilution, Cell Signaling, The Netherlands). Thereafter, the sections were
incubated with a Dako EnVision FLEX + mouse or rabbit linker for
15 min followed by incubation with Dako EnVision FLEX/horseradish
peroxidase for an additional 30 min. For visualization of staining, the
sections were treated with 303-diaminobenzidine tetra-hydrochloride
(DAB) for 10 min, counterstained with hematoxylin and mounted in a
toluene-free mounting medium (Dako, Danmark A/S).
Statistical analysis. Student’s t-test was used to analyze differences in
the fluorescence intensities of the conjugate in tumor and normal tissues.
The same test was also employed to analyze the colocalization data
obtained from ImageJ. A P < 0.05 value was considered to be
statistically significant.
RESULTS
Uptake, localization and colocalization of the conjugate in
tumor
Figure 2 shows an example of transmission, GFP and IR700DX
images that were used to quantify the uptake of conjugate by
tumor and its surrounding normal tissues. The red fluorescent
IR700DX of the conjugate was already seen in the tumor and its
surrounding vessels (arrow in Fig. 2) with some vascular
branches in the tumor areas at 4 h after its administration. At 24
and 48 h, more conjugate was distributed in the tumor with little
in the vessels (arrows in Fig. 2). Quantitative measurements with
image analyses demonstrate that the conjugate in the tumor tissue
increased with times after i.v. injection with a peak at 24–48 h
and was significantly higher than that in the surrounding blood
vessels and normal connective tissue (P < 0.05; Fig. 3).
Figure 4 shows a negative value of Pearson’s R value in the sam-
ples taken before conjugate injection. At 4 h after conjugate injec-
tion, very low values of Pearson’s R value were seen between the
conjugate IR700DX and tumor GFP. The analyses of the images
taken at 24 and 48 h after conjugate injection show higher values of
the correlation parameter (Fig. 4), demonstrating a higher degree of
colocalization of the two different fluorescent signals. Furthermore,
high values of Mander’s tM1 at all time points illustrate that the
fraction of conjugate IR700DX was largely colocalized with the
tumor GFP areas (Fig. 4). Statistically, Pearson’s R value shows a
significant difference between 4 and 24 h (P = 0.002) with no sig-
nificant difference between 24 and 48 h (P = 0.153). These statis-
tical data may indicate a significant difference between 4 and 24–
48 h in terms of the degree of pixel-intensity correlation of conju-
gate IR700DX and tumor GFP. However, the statistical analyses
of Mander’s tM1 show no significant difference between 4 and
24–48, suggesting a high degree of colocalization correlation of
the two different signals between the different time points.
Vascular responses to targeted PDT
Four animals with the skin-fold window chamber tumor model
were used to study normal and tumor vascular responses in real-
time during targeted PDT (Fig. 5). The extent of the vascular
responses was also semiquantified and presented in the Table 1.
No changes in the large blood vessels in normal tissue around
tumors were seen at 5 min after targeted PDT in two out of four
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animals (T-1 & T-2), but the vessels were slightly constricted at
2 h and severely contracted at 24 h. At 48 h after targeted PDT,
the function of all vessels had recovered with visible blood flow
in the two animals (Fig. 5, Table 1). In the third animal, a slight
constriction of the large blood vessels was observed at 5 min after
targeted PDT followed by apparent dilatation of the vessels at 2 h
before the recovery of their function at 24 h (Fig. 5, Table 1).
Similarly, the large vessels were dilated at 2 h after PDT in the
fourth animal with a recovery at 24 h (Fig. 5, Table 1). No per-
manent damage to the large blood vessels was observed at 48 h
after PDT in all the four animals (Fig. 5). Furthermore, the vascu-
lar responses in the four animals were determined by imaging rho-
damine dextran 2 MDa extravasation at 2 h after targeted PDT.
Figure 6 shows no leakage of rhodamine dextran 2 MDa in all
the four tumors, indicating that the targeted PDT does not cause a
severe damage to tumor vascular structures. However, there was
some Rhodamine leakage in the tumor-surrounding normal tissues
(red regions highlighted in Fig. 6).
Tumor destruction by targeted PDT
The tumor tissue response to the targeted PDT was examined by
histopathology and IHC. Untreated tumors in the skin-fold win-
dow chamber demonstrate viable tumor cells with no damaged
alterations by histopathology with H.E. staining (Control in
Fig. 7). IHC of the control tumors showed homogenous cell sur-
face expression of EGFR and nuclear staining of the proliferative
factor Ki67 in individual tumor cells (Fig. 7). In addition, some
Figure 2. Kinetic localization patterns of the cetuximab–IR700DX conjugate in the OSC19 tumor and its surrounding normal tissues in the skin-fold
window chamber at 0, 4, 24 and 48 h after i.v. injection. The images were obtained from one of the tumors examined including transmission, green
tumor GFP signals and red cetuximab–IR700DX conjugate together with arrows for the blood vessels in the surrounding normal tissue. The images were
acquired with the intravital LSM (bars: 500 µm). For the details, see the Section of Materials and Methods.
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positive cleaved caspase-3 cells were seen (Fig. 7). The tumors
treated with the targeted PDT have shown an extensive damage
with necrotic and apoptotic (nuclear condensation) cell death
(H.E. in Fig. 7). Some slight damage in the overlying normal
skin tissue was also seen (Fig. 7). In addition, inhomogenous,
weak staining of EGFR and of the proliferative factor, Ki67 sug-
gests a decreased expression of EGFR and Ki67 in tumor cells.
Moreover, the cleaved caspase-3, a pivotal factor for the execu-
tion of cell apoptosis, was apparently overexpressed in the tumor
cells, indicating apoptotic cell death after the targeted PDT
(Fig. 7). LC3, a central protein in the autophagy pathway and a
marker of autophagosomes, was not expressed (data not shown),
suggesting no involvement of autophagy in the tumor cell death.
Interestingly, no congestion and hemorrhage of blood vessels
were seen in the tumors and surrounding normal tissues (Fig. 8).
IHC showed typical brownish nuclei of positive staining of HIF-
1a, a well-known transcription factor for regulating cellular
response to hypoxia, in the epidermal cells, but not in the
beneath tumor cells (Fig. 8). This was consistent with no severe
vascular damage demonstrating that the tumor destruction by the
targeted PDT was largely due to a direct killing effect rather than
an indirect effect via vascular damage.
DISCUSSION
A dorsal skin-fold window chamber tumor model in combination
with confocal imaging technologies can offer a unique opportu-
nity to quantitatively analyze in real-time the fluorescence-based
pharmacokinetics and biodistribution of the cetuximab/IR700DX
conjugate in the OSC-19 tumor and its surrounding normal tis-
sues in living athymic mice. In addition, this technique can visu-
alize the dynamic patterns of normal and tumor vascular
responses to the targeted PDT. Such studies would help to opti-
mize parameters affecting the targeted PDT efficacy. Cetuximab/
IR700DX was taken up by the tumor cells already at 4 h and
peaked at 24 and 48 h after administration. It was still detectable
in the blood at 4 h after administration and less at later time
points. A 24 h drug–light interval was therefore chosen for the
subsequent targeted PDT of the tumor in this study. The same
interval is also being used in the ongoing clinical trial of the tar-
geted PDT in head and neck cancer patients. While cetuximab is
a chimeric (mouse/human) antibody against human EGFR, it does
not bind to mouse EGFR. The increase in fluorescence in normal
mouse tissues observed in this model is likely to be the result of
content in the blood circulation and unspecific uptake of the con-
jugate. It should be mentioned that IR700DX in a free form was
not included in this study because this water-soluble dye has been
shown in several reports to be little taken up by tumor tissues
with little subsequent photodynamic effects (29–31,40).
The microscopy-based methods to study colocalization of
markers in biological systems are often qualitatively descriptive
rather than quantitative. For example, to overlap a green and a
red fluorescent images for two various markers with a resultant
Figure 3. Kinetic patterns of uptake of the cetuximab–IR700DX conju-
gate by the OSC19 tumor and its surrounding normal blood vessels and
connective tissue in the skin-fold window chamber at various times after
i.v. injection. The amounts of the conjugate in the tissues were measured
by quantifying the fluorescent signals of the conjugate IR700DX with the
intravital LSM as described in the Section of Materials and Methods.
Figure 4. Image analyses of the colocalization correlation parameters of (A) Pearson’s R value and (B) Manders’ tM1 for the conjugate IR700DX and
tumor GFP using the coloc2 plugin of ImageJ. Zero hour in the plots is prior to the conjugate administration. The background of the 0 h images is sub-
tracted in Manders’ tM1 plot.
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yellow color image is still commonly used to assess colocaliza-
tion. However, such a visual estimation does not allow quantifi-
cation of the degree of colocalization. Based on the initial work
by Pearson in 1896 (41), several statistical methods of pixel-in-
tensity correlation have been developed to quantify the degree of
colocalization of two fluorescence channels (42,43). The signifi-
cant lower level of Pearson’s R value at 4 h than 24 h (Fig. 4)
is in agreement with the pixel-intensity-based “uptake” data with
a lower amount of IR700DX in the tumors at 4 h than 24–48 h
(Fig. 3). Further, the relative high values of Manders’ tM1 as a
colocalization quantifier demonstrate a high fraction of positive
IP700DX areas that colocalizes with the tumor GFP. No signifi-
cant difference of Mander’s tM1 in the images taken at 4, 24
and 48 h suggests that IR700DX was localized in the tumor cells
with a relative high specificity during the study period.
Microvascular structures of a tumor are usually vulnerable to
PDT. This starts with recoverable functional disturbance, such as
vasoconstriction and vasodilatation, in the arterioles, capillaries
and postcapillary venules. This often results in aggregation of
blood cells and thereby reduced blood flow and possibly finally
complete stasis (44–46). The vasoconstriction may be caused by
the release of thromboxane, a potent vasoconstrictor formed from
damaged cell membrane lipids such as from platelets (47). Con-
versely, histamine, a powerful vasodilator released from the
degranulation of mast cells, may induce the vasodilatation (48).
Furthermore, if a photosensitizer is localized in the collagen
Figure 5. Kinetic changes of vascular responses of four treated tumor-bearing animals in the window chamber were determined by the intravital trans-
mission LSM at prior to and 5 min, 2, 24 and 48 h after the targeted PDT (bars: 2000 µm). For the details, see the Section of Materials and Methods.
Table 1. Vascular responses to targeted PDT.
Tumors Prior to 5 min 2 h 24 h 48 h
Tumor-1   + ++ 
Tumor-2   + ++ 
Tumor-3  + +  
Tumor-4   +  
EGFR-overexpressing human head and neck OSC-19-luc2-cGFP tumor
in the mouse skin-fold window chamber was irradiated with a 690 nm
laser at a dose of 100 J cm2 (50 mW cm2) at 24 h after the i.v. injec-
tion of Cetuximab-IR700DX conjugate. The vascular responses were
semiquantified by () no changes in the vascular lumen with normal
blood flow, (+) slight changes in narrowing or dilating the vascular
lumen, but still with visible blood flow and (++) severely changes in nar-
rowing the vascular lumen and/or shutting down the vessels with no
detectable blood flow.
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fibers and connective tissue elements of the subendothelial zone
of the capillary wall, this may lead to permanent vascular dam-
age after light activation. No permanent vascular damage in this
study suggests that the targeted PDT may not damage the suben-
dothelial zone of the vasculature. Normally, the effects of hypox-
ia/anoxia on tumor due to functional alterations of vessels are
limited if they do not last for a long time, as an effective PDT
usually requires a permanent vascular damage (49). The initial
mild to severe constriction followed by dilation of the vascular
responses was observed up to 24 h after the targeted PDT in the
present study. This might be due to a nonspecific photodynamic
effect of circulating conjugates on the vascular walls, since some
conjugate in the blood vessels was still seen at 24 h after injec-
tion (Fig. 3). Such microvascular effects were not permanent, as
the vascular functions were recovered at 48 h after the targeted
PDT. Moreover, the rhodamine dextran 2 MDa extravasation
confirmed no leakage of the tumor vessels, suggesting no struc-
tural damage of the tumor vessels. Consistently, no expression of
HIF-1a in the tumor cells (Fig. 8) indicates that the targeted
PDT-induced transient vascular alterations did not result in a sev-
ere hypoxic condition in the tumors.
Histopathology and IHC demonstrate an extensive necrotic
destruction of the two tumors 48 h after the targeted PDT with
no signs of hemorrhage. Thus, such tumor damage may not
involve the blood vessels. Only slight damage of the overlying
epidermis was observed, most likely the result of unspecific
uptake of the conjugate. The binding of the conjugate to the
EGFR of the OSC-19 tumor cells most likely played a crucial
role in the direct killing of tumor cells by the targeted PDT.
EGF, a small mitogenic protein, binds to EGFR on the cell
surface to induce autophosphorylation of several tyrosine resi-
dues in the C-terminal domain of EGFR. This leads to a stimula-
tion of its intrinsic tyrosine kinase activity. It is well known that
overexpression of EGFR promotes cell cycle progression from
the G1 to S phase to increase cell proliferation. In this study, the
down-expression of EGFR with downregulation of the prolifera-
tive factor Ki67 of the tumor cells as seen by IHC supports the
tumor damage via targeting EGFR of the targeted PDT.
Figure 6. The fluorescent rhodamine dextran 2 MDa was imaged immediately after its i.v. injection as a marker for vascular leakage in four tumor-
bearing animals at 2 h after the targeted PDT. The images were acquired with the intravital LSM including transmission, green tumor GFP, yellow rho-
damine dextran 2MDa and merge of GFP and Rhodamine (bars: 1000 µm). For the details, see the Section of Materials and Methods. The red regions
in the T-2 and T-4 indicate some leakage of rhodamine dextran 2 MDa from the normal vessels around the tumors.
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Figure 7. Hematoxylin–eosin (H.E.) staining and immunohistochemistry of EGFR, Ki67 and cleaved caspase-3 of tumors at 48 h after the targeted
PDT (the bars in H.E. images: 100 µm for the left column of images and 50 µm for the middle column of images). EPI, epidermis; T, tumor. A control
tumor is also included (the bar in the H.E. image is 50 µm for the right column of images).
Figure 8. Immunohistochemistry of HIF-1a in a tumor at 48 h after the targeted PDT. EPI, epidermis; T, tumor. Epidermal cells show HIF-1a staining
of brownish nuclei served as “internal” positive controls, while no HIF-1a is seen in the subcutaneous tumor cells. The bars: 100 µm for the left image
and 50 µm for the right images.
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Since the first report by Agarwal et al. in 1991 on the apop-
totic induction by PDT with chloroaluminium phthalocyanine
(50), a large number of studies have concluded that PDT can
induce cell death through apoptosis. Apoptosis, or programmed
cell death, is a form of cell death distinct from necrosis with
respect to the characteristics of morphology and biochemistry.
Cytosolic aspartate-specific (cysteine) proteases, called caspases,
are responsible for the induction of apoptosis. All apoptotic cas-
pases exist in cells as an inactive form. When cells undergo
apoptosis, these caspases become activated through one or more
sequential proteolytic events that cleave the single peptide pre-
cursor into large and small fragments. Among them, the caspase-
8, caspase-9 and caspase-3 appear to play a crucial role in the
degradative events in apoptosis. Currently, there are two well-
characterized pathways of caspase-activating cascades that regu-
late apoptosis: the cell surface death receptor pathway via cleav-
age of caspase-8 and the mitochondrial-initiated pathway via
cleavage of caspase-9. The cleaved caspase-8 or caspase-9 then
activates the downstream executioner, caspase-3. The nuclear
condensation of some tumor cells with the upregulation of
cleaved caspase-3 in this study suggests an apoptotic induction
probably through a receptor-mediated pathway after directly tar-
geting EGFR by the targeted PDT. No positive detection of the
LC-3 as a marker of autophagy may indicate no involvement of
the autophagic process in this study.
CONCLUSIONS
The fluorescent kinetic uptake and localization patterns of the
cetuximab/IR700DX conjugate in the EGFR-overexpressing human
head and neck OSC-19 tumors in the mouse skin-fold window
chamber were studied in real-time. The amounts of the conjugate
peaked at 24–48 h in the tumor tissue. The light exposure then
caused initial contraction and subsequent dilatation of the normal
blood vessels followed by functional recovery at 48 h. No leakage
of the rhodamine dextran 2 MDa within the tumor tissue, together
with negative staining of HIF-1a in the tumor cells by IHC, sug-
gests no substantial damage to the tumor vascular structure, neither
a severe hypoxic condition in the tumors after the targeted PDT.
Furthermore, the extensive tumor necrosis shown by histopathol-
ogy with H.E. staining and the cleavage of caspase-3 by IHC in the
tumor cells demonstrates both necrotic and apoptotic cell deaths
are involved in the tumor destruction. These results suggest that
such an effective modality was largely due to a direct effect on the
EGFR-overexpressing OSC-19 tumor cells via the specific light-ac-
tivated cetuximab–IR700DX conjugate rather than an indirect
effect from vascular damage. This study demonstrates that targeted
PDT with the cetuximab/IR700DX conjugate may have a potential
for treating EGFR expressing tumors.
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